Clinical Radiology
Volume 63, Issue 7 , Pages 765-773 , July 2008

Impact of the introduction of integrated PET-CT into the preoperative staging pathway of patients with potentially operable oesophageal carcinoma

Received 17 September 2007 ,Revised 30 January 2008 ,Accepted 6 February 2008.

References 

  1. Liberale G, Van Laethem JL, Gay F, et al. The role of PET scan in the preoperative management of oesophageal cancer. Eur J Surg Oncol. 2004;30:942–947
  2. Farrokh D, Barry AS. Neoplasms of the esophagus and stomach. Semin Nucl Med. 2004;34:198–208
  3. Munden RF, Macapinlac HA, Eramus JJ. Esophageal cancer: the role of integrated CT-PET in initial staging and response assessment after preoperative therapy. J Thorac Imaging. 2006;21:137–145
  4. Rosch T. Endosonographic staging of esophageal cancer: a review of literature results. Gastrointest Endosc Clin N Am. 1995;3:537–547
  5. Stahl A, Stollfuss J, Ott K, et al. FDG PET and CT in locally advanced adenocarcinomas of the distal oesophagus. Clinical relevance of a discordant PET findings. Nuklearmedizin. 2005;44(6):249–255[quiz N55-6]
  6. Yuan S, Yu Y, Chao KS, et al. Additional value of PET/CT over PET in assessment of locoregional lymph nodes in thoracic esophageal squamous cell cancer. J Nucl Med. 2006;47:1255–1259
  7. Green FL, American Joint Committee on Cancer (AJCC) . In:  Green FL,  Page DL,  Fleming ID, et al. editor. Cancer Staging Manual. 6th ed.. New York: Springer-Verlag; 2002;
  8. van Westreenen HL, Westerterp M, Bossuyt PM, et al. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol. 2004;22:3805–3812
  9. Choi JY, Lee KH, Shim YM, et al. Improved detection of individual nodal involvement in squamous cell carcinoma of the esophagus by FDG-PET. J Nucl Med. 2000;41:808–815
  10. Bar-Shalom R, Guralnik L, Tsalic M, et al. The additional value of PET/CT over PET in FDG imaging of oesophageal cancer. Eur J Nucl Med Mol Imaging. 2005;32:918–924
  11. Flanagan FL, Dehdashti F, Siegel BA, et al. Staging of esophageal cancer with F-18-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol. 1997;168:417–424
  12. Rankin S, Taylor H, Cook G, et al. Computed tomography and positron emission tomography in the preoperative staging of oesophageal carcinoma. Clin Radiol. 1998;53:659–665
  13. McAteer D, Wallis F, Couper G, et al. Evaluation of 18F-FDG positron emission tomography in gastric and oesophageal carcinoma. Br J Radiol. 1999;72:525–529
  14. Meltzer CC, Luketich JD, Friedman D, et al. Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography. Clin Nucl Med. 2000;25:882–887
  15. Wren SM, Stijns P, Srinivas S. Positron emission tomography in the initial staging of esophageal cancer. Arch Surg. 2002;137:1001–1006
  16. Himeno S, Yasuda S, Shimada H, et al. Evaluation of esophageal cancer by positron emission tomography. Jpn J Clin Oncol. 2002;32:340–346
  17. Rasanen JV, Sihvo EI, Knuuti MJ. Prospective analysis of accuracy of positron emission tomography, computed tomography, and endoscopic ultrasonography in staging of adenocarcinoma of the esophagus and the esophagogastric junction. Ann Surg Oncol. 2003;10:954–960
  18. Heeren PA, Jager PL, Bongaerts F, et al. Detection of distant metastases in esophageal cancer with (18)F-FDG-PET. J Nucl Med. 2004;45:980–987
  19. Lerut T, Coosemans W, Decker G, et al. Cancer of the esophagus and gastro-esophageal junction: potentially curative therapies. Surg Oncol. 2001;10:113–122
  20. Hossein J, Robert WH, Peter SC. 2-Deoxy-2-[F-18]fluoro-d-glucose-positron emission tomography/computed tomography imaging evaluation of esophageal cancer. Mol Imaging Biol. 2006;8:193–200
  21. Yeung HW, Macapinlac HA, Mazumdar M, et al. Incremental value over computed tomography. Clin Positron Imaging. 1999;2:255–260
  22. Flamen P, Lerut A, Van Cutsem E, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol. 2000;18:3202–3210
  23. Lerut T, Flamen P, Ectors N, et al. Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: a prospective study based on primary surgery with extensive lymphadenectomy. Ann Surg. 2000;232:743–752
  24. Imdahl A, Hentschel M, Kleimaier M, et al. Impact of FDG-PET for staging of oesophageal cancer. Langenbecks Arch Surg. 2004;389:283–288
  25. Kole AC, Plukker JT, Nieweg OE, et al. Positron emission tomography for staging of oesophageal and gastroesophageal malignancy. Br J Cancer. 1998;78:521–527
  26. Luketich JD, Friedman DM, Weigel TL, et al. Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans. Ann Thorac Surg. 1999;68:1133–1136[discussion: 1136–7]
  27. Fukunaga T, Okazumi S, Koide Y, et al. Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET. J Nucl Med. 1998;39:1002–1007
  28. Joon YC, Hong-Ju J, Young MS, et al. 18F-FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: prognostic implications. J Nucl Med. 2004;45:1843–1850
  29. Voormolen MHJ, Van Deelen RAJ, Tilanus HW, et al. Esophageal carcinoma and multiple primary tumors. Dis Esophagus. 1995;8:218–221
  30. Kagei K, Hosokawa M, Shirato H, et al. Efficacy of intense screening and treatment for synchronous second primary cancers in patients with esophageal cancer. Jpn J Clin Oncol. 2002;32:120–127
  31. van Westreenan HL, Westerterp M, Jager PL, et al. Synchronous primary neoplasms detected on 18F-FDG PET in staging of patients with esophageal cancer. J Nucl Med. 2005;46:1321–1325
  32. Graham MM, Peterson LM, Hayward RM. Comparison of simplified quantitative analyses of FDG uptake. Nucl Med Biol. 2000;27:647–655
  33. Ahuja V, Coleman RE, Herndon J, et al. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with non-small cell lung carcinoma. Cancer. 1998;83:918–924
  34. Oshida M, Uno K, Suzuki M, et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-d-glucose. Cancer. 1998;82:2227–2234
  35. Oyama N, Akino H, Suzuki Y, et al. Prognostic value of 2-deoxy-2-[F-18]fluoro-d-glucose positron emission tomography imaging for patients with prostate cancer. Mol Imaging Biol. 2002;4:99–104
  36. van Westreenen HL, Plukker JTM, Cobben DCP, et al. Prognostic value of the standardized uptake value in esophageal cancer. AJR Am J Roentgenol. 2005;185:436–440
  37. Taira AV, Herfkens RJ, Ghambhir SS, et al. Detection of bone metastases: assessment of integrated FDG PET/CT imaging. Radiology. 2007;243:204–211

PII: S0009-9260(08)00083-4

doi: 10.1016/j.crad.2008.02.002

Clinical Radiology
Volume 63, Issue 7 , Pages 765-773 , July 2008

Article Tools

* Image Usage & Resolution